Agio RUS Llc

Agio RUS Llc is a pharmaceutical importer based in Moscow, Russia, specializing in the procurement of finished pharmaceutical formulations. Established to meet the growing demand for diverse therapeutic products, Agio RUS Llc plays a pivotal role in Russia's pharmaceutical distribution network. The company operates as a primary wholesaler, sourcing a wide array of pharmaceutical products from international suppliers to cater to the needs of the Russian market.

The company's headquarters are located at 115230, Moscow, Kashirskoye Shosse, 3 Building 2/4 Room 5, Moscow, Russia. Agio RUS Llc's parent company, Agio Pharmaceuticals Limited, is a prominent pharmaceutical manufacturer based in India. This affiliation enables Agio RUS Llc to leverage a robust supply chain, ensuring a steady influx of high-quality pharmaceutical products into Russia.

Agio RUS Llc's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Russia. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are evident through its extensive import activities. Between 2022 and 2026, Agio RUS Llc facilitated 276 shipments from India, underscoring its capacity to manage substantial volumes of pharmaceutical imports. The primary port of entry for these shipments is Novorossiysk, a major port on the Black Sea, which serves as a critical hub for the importation of goods into Russia.

The company's geographic coverage spans the entirety of Russia, ensuring that pharmaceutical products reach both urban centers and remote regions. This extensive reach is facilitated by a combination of direct distribution channels and partnerships with local wholesalers and retailers, enabling Agio RUS Llc to effectively serve the diverse needs of the Russian pharmaceutical market.

In Russia's pharmaceutical supply chain, Agio RUS Llc functions primarily as a wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a consistent supply of essential medications to the Russian market. This role is crucial in a market where domestic production may not fully meet the demand for certain pharmaceutical products. Agio RUS Llc's operations bridge the gap between international manufacturers and Russian healthcare providers, facilitating the availability of a wide range of therapeutic options.

The company's focus on importing finished formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a strategic decision to streamline the supply chain and reduce the complexities associated with local manufacturing. This approach allows Agio RUS Llc to concentrate on distribution and logistics, ensuring timely delivery of ready-to-use pharmaceutical products to the Russian market.

Agio RUS Llc exhibits a high degree of sourcing concentration, with a single supplier—Agio Pharmaceuticals Limited—accounting for the entirety of its pharmaceutical imports. Between 2022 and 2026, the company imported products worth $5.2 million USD across 276 shipments, all sourced from Agio Pharmaceuticals Limited.

This single-source dependency presents both strategic advantages and potential risks. On the positive side, a sole supplier relationship can lead to streamlined operations, consistent product quality, and favorable terms due to the volume of business conducted. However, this concentration also exposes Agio RUS Llc to risks associated with supply chain disruptions, such as production delays, geopolitical issues, or regulatory changes affecting the supplier.

The stability of this relationship is crucial. The consistent volume of imports over the years suggests a strong and reliable partnership between Agio RUS Llc and Agio Pharmaceuticals Limited. Nonetheless, it is imperative for Agio RUS Llc to monitor this dependency and consider diversifying its supplier base to mitigate potential risks and ensure a resilient supply chain.

Agio RUS Llc's supply chain resilience is closely tied to its exclusive partnership with Agio Pharmaceuticals Limited. This singular supplier relationship simplifies logistics and quality control processes but also means that any disruption at the supplier's end can significantly impact Agio RUS Llc's operations.

The company's focus on importing finished pharmaceutical formulations from India indicates a strategic choice to leverage India's established pharmaceutical manufacturing capabilities. India is renowned for its adherence to international Good Manufacturing Practices (GMP), ensuring that the imported products meet high-quality standards. However, Agio RUS Llc's reliance on a single supplier and a specific geographic region for its imports may expose it to risks related to geopolitical tensions, regulatory changes, or logistical challenges affecting the supply chain.

To enhance supply chain resilience, Agio RUS Llc may consider diversifying its supplier base and exploring alternative sourcing options. Engaging with multiple suppliers across different regions can provide a buffer against potential disruptions and contribute to a more robust and flexible supply chain.

Agio RUS Llc's sourcing pattern, characterized by a high degree of concentration with a single supplier, has significant strategic implications. While this approach can lead to operational efficiencies and strong supplier relationships, it also introduces vulnerabilities related to supply chain disruptions.

For Indian exporters, Agio RUS Llc's exclusive partnership with Agio Pharmaceuticals Limited presents both challenges and opportunities. The existing supplier relationship may limit the potential for new entrants; however, there may be opportunities to offer complementary products or services that align with Agio RUS Llc's needs. Understanding the dynamics of Agio RUS Llc's supply chain and identifying areas where additional value can be provided will be crucial for any new Indian suppliers seeking to enter this market.

The regulation of pharmaceutical imports into Russia is governed by the Federal Service on Surveillance in Healthcare, known as Roszdravnadzor. This federal executive body is responsible for ensuring the safety, quality, and efficacy of medical products circulating within the Russian Federation.

Key legislation governing pharmaceutical imports includes Federal Law No. 61-FZ "On the Circulation of Medicinal Products," which outlines the procedures for the importation, registration, and distribution of medicinal products in Russia. This law establishes the framework for ensuring that imported pharmaceuticals meet the necessary standards for public health and safety.

The marketing authorization pathway for Indian generics involves obtaining a registration certificate from Roszdravnadzor. This process requires the submission of comprehensive documentation, including evidence of the product's quality, safety, and efficacy, as well as compliance with Russian regulatory standards. The registration process is designed to ensure that all medicinal products, including generics, meet the stringent requirements set forth by Russian authorities.

Import licensing for pharmaceutical products in Russia is a two-step process. First, permits are issued by Roszdravnadzor, which oversees the safety and quality of medical products. Following the issuance of permits, licenses are granted by the Ministry of Industry and Trade, authorizing the importation and distribution of the pharmaceutical products within Russia.

Imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards recognized by the Russian Federation. This includes adherence to GMP certifications from reputable organizations such as the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that the manufacturing processes meet international quality standards, which is crucial for the safety and efficacy of the imported products.

Additionally, wholesale distribution authorization is required for entities involved in the importation and distribution of pharmaceutical products. This authorization ensures that distributors operate in compliance with Russian regulations and maintain the integrity of the pharmaceutical supply chain.

Imported pharmaceutical products are subject to batch testing to verify their quality, safety, and efficacy. This testing is conducted by accredited laboratories to ensure that the products meet the standards set by Russian regulatory authorities.

Stability requirements for pharmaceutical products are established to ensure that the products remain effective and safe throughout their shelf life. These requirements are based on international guidelines and are enforced by Roszdravnadzor.

Labeling language requirements stipulate that all pharmaceutical product labels must be in Russian. This ensures that consumers and healthcare professionals can accurately read and understand the product information.

Serialization mandates require that pharmaceutical products be uniquely identified with serial numbers. This system enhances traceability and helps prevent counterfeit products from entering the market.